A new study has found that glucosamine, one of the most widely used over-the-counter supplements in America, may accelerate cognitive decline in people with Alzheimer's disease and related dementias. Researchers at the University of Florida discovered that glucosamine crosses the blood-brain barrier and overstimulates a harmful metabolic process already running in overdrive in Alzheimer's brains, potentially worsening disease progression.

The findings come from a comprehensive analysis combining 12 years of electronic health records from over 4,600 patients, laboratory studies in mice, and examination of human brain tissue. The results suggest that what helps joints may harm the brain in people with cognitive decline, raising important questions for the millions of seniors currently taking this supplement.

What Is Hyperglycosylation and Why Does It Matter?

At the heart of this discovery is a metabolic process called hyperglycosylation, a condition in which proteins in the brain receive too many "sugar tags." In healthy brains, these sugar structures help proteins fold correctly and communicate with each other. But in Alzheimer's disease, this tagging system goes haywire, adding excessive sugar modifications that gum up cellular machinery and interfere with normal brain function.

Researchers used advanced spatial metabolomics and glycomics technology to map this process in both Alzheimer's mouse models and post-mortem human brain tissue. They found that the Alzheimer's brain consistently shows signs of hyperglycosylation, suggesting this metabolic disruption is a core feature of the disease, not just a side effect.

Glucosamine, a naturally occurring sugar-related molecule found in shellfish shells and corn, easily crosses the blood-brain barrier and feeds directly into the pathways that create these excessive sugar tags. This is where the problem begins: in a brain already struggling with overactive sugar-tagging, glucosamine acts as fuel for an already dysregulated system.

How Strong Is the Link Between Glucosamine and Alzheimer's Progression?

The research team analyzed deidentified health records from the University of Florida Health system spanning 2012 to 2024, identifying 1,896 patients with established Alzheimer's disease and related dementias (ADRD) and 2,750 with mild cognitive impairment (MCI). Remarkably, 8% of both groups reported taking glucosamine supplements, a proportion the researchers found surprisingly high.

After controlling for age, sex, and other demographic factors, the data revealed striking associations. Patients with mild cognitive impairment who took glucosamine were 25% more likely to progress to full-blown dementia. Among those already living with Alzheimer's disease, glucosamine use was linked to a 25% increase in short-term mortality risk. Notably, this mortality spike did not appear in the MCI group, suggesting the Alzheimer's brain may be uniquely vulnerable to this metabolic stress.

While these findings are based on observational data rather than a controlled clinical trial, the consistency across multiple research approaches strengthens the evidence. The researchers emphasized that these are associations, not proof of direct causation, but the pattern is compelling enough to warrant urgent clinical attention.

What Do Animal Studies and Brain Tissue Reveal?

To test whether glucosamine directly causes the problem, researchers conducted experiments in genetically modified mice engineered to develop Alzheimer's-like pathology. When given glucosamine, these mice showed significantly increased sugar attachment to brain proteins. More importantly, their cognitive deficits worsened, particularly in "social memory," or the ability to recognize and remember other mice.

The breakthrough came when researchers chemically blocked the sugar-tagging process. When they suppressed this attachment mechanism, the cognitive deficits reversed, demonstrating that hyperglycosylation is not just a marker of disease but an active driver of neurological decline.

Post-mortem examination of brain tissue from confirmed Alzheimer's cases confirmed the laboratory findings. Tissue samples from the UF Neuromedicine Brain and Tissue Bank showed dramatically elevated sugar-tagging footprints in Alzheimer's brains compared to healthy controls, validating the human relevance of the mouse model results.

How Does This Shift Our Understanding of Alzheimer's?

For decades, Alzheimer's research has focused heavily on two hallmark pathologies: amyloid-beta plaques and tau tangles. These protein aggregates accumulate in the brain and are believed to trigger neurodegeneration. However, this new research establishes metabolic dysregulation, specifically hyperglycosylation, as a primary and active driver of disease, not merely a passive consequence of plaque and tangle formation.

The discovery opens a new therapeutic avenue that could complement existing approaches targeting amyloid and tau. Rather than waiting for drugs that clear plaques, researchers can now explore ways to normalize glycan metabolism and reduce excessive sugar-tagging in the brain.

"Our results suggest that altered metabolism is a significant contributor to Alzheimer's progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer's plaques and tangles," said Ramon Sun, director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of the University of Florida's McKnight Brain Institute.

Ramon Sun, Director of the Center for Advanced Spatial Biomolecule Research, University of Florida McKnight Brain Institute

What Should People With Cognitive Decline Know?

The implications for patients are significant. Millions of older adults take glucosamine for arthritis and joint pain, often without discussing it with their doctors. For those with a family history of Alzheimer's, a diagnosis of mild cognitive impairment, or established dementia, this research suggests a conversation with their healthcare provider about whether glucosamine is appropriate.

The findings do not mean glucosamine is harmful for everyone. The research specifically highlights the vulnerability of the Alzheimer's brain to this metabolic pathway. People taking glucosamine for joint health without cognitive concerns may face a different risk-benefit calculation, though the researchers note that more investigation is needed.

Steps to Take If You're Concerned About Glucosamine and Cognitive Health

• Consult Your Doctor: If you are taking glucosamine and have concerns about cognitive decline, memory loss, or a family history of Alzheimer's disease, schedule a conversation with your primary care physician or neurologist about whether the supplement is appropriate for you.
• Review Your Supplement List: Make a complete list of all supplements and over-the-counter medications you take, including glucosamine, and bring it to your next medical appointment so your doctor can assess potential interactions or risks specific to your health status.
• Explore Alternative Joint Support: If you decide to discontinue glucosamine, ask your healthcare provider about other approaches to managing joint pain, such as physical therapy, anti-inflammatory medications, or other supplements that may not affect brain metabolism in the same way.
• Monitor Cognitive Changes: If you are over 65 or have risk factors for Alzheimer's disease, consider periodic cognitive screening and maintain open communication with your doctor about any changes in memory, thinking, or daily functioning.

What Happens Next in This Research?

The researchers acknowledge that their findings, while compelling, are preliminary and require validation in a prospective clinical trial where some patients are randomly assigned to take glucosamine and others receive a placebo. Such a trial would provide definitive proof of causation rather than association.

In the meantime, the discovery of hyperglycosylation as a metabolic driver of Alzheimer's opens new doors for drug development. Researchers can now target glycan biosynthetic enzymes to reduce excessive sugar-tagging in the brain. The fact that genetic knockdown of these enzymes improved cognitive outcomes in mice suggests this approach is feasible.

"In the United States, there are about 7 million people living with Alzheimer's and millions more with related dementias such as Lewy body or frontotemporal dementia. A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse," noted Ramon Sun.

Ramon Sun, Director of the Center for Advanced Spatial Biomolecule Research, University of Florida McKnight Brain Institute

This research represents a significant shift in how scientists think about Alzheimer's disease. Rather than viewing metabolic changes as secondary consequences of neurodegeneration, researchers now recognize them as primary drivers that can be targeted therapeutically. For the millions of people living with Alzheimer's and related dementias, and for those at risk, this metabolic perspective offers new hope for slowing or preventing cognitive decline.